# Summary **Introduction:** In recent years, innovative health research has been moving quickly towards a new paradigm known as “personalized medicine”, which consists of a medical model that uses characterization of individuals’ phenotypes and genotypes to tailor the right therapeutic strategy for the right person at the right time. In this framework, “personalized prevention” aims to prevent the onset, progression, and recurrence of diseases through the adoption of targeted interventions that consider the biological environmental and behavioral characteristics, as well as the socio-cultural environment. In this context, chronic noncommunicable diseases merit specific attention due to their rising prevalence and incidence. The question is whether there is any biomarker or combination of biomarkers that can help to better identify subgroups of individuals with different risks of developing a particular disease, in which specific preventive strategies could have an impact on clinical outcomes. **Objective:** To systematically map and examine the evidence for biomarkers that are available or under development in cancer, cardiovascular and neurodegenerative diseases that are or can be used for personalized prevention in the general population, in clinical or public health settings. **Methods:** A rapid scoping review will be conducted (Feb – Jun 2023), based on a common framework with some adjustments to suit each specific topic (cancer, cardiovascular or neurodegenerative diseases). Medline, Embase and the CDC-Authored Genomics and Precision Health Publications Databases will be searched to identify publications between 2020 and 2023. The 10% of the total papers –in every screening and data extraction phase– will be assessed by two reviewers, to clarify and discuss inclusion and exclusion criteria; the remaining papers will be evaluated by one reviewer. The following information will be extracted from the publications selected for inclusion: source type, citation details, country, inclusion/exclusion criteria (population, concept, context, type of evidence source), study methods, and key findings relevant to the review question/s. The selection criteria and the extraction sheet will be pre-tested. Relevant biomarkers for risk prediction and stratification will be recorded. Results will be presented graphically using an evidence map. **Inclusion criteria:** Population –general adult populations or adults from specific pre-defined high-risk subgroups–; concept –all studies focusing on molecular, cellular, physiological, or imaging biomarkers used for individualized primary or secondary prevention of the diseases of interest– ; context –clinical or public health settings– .